Eclampsia is a serious obstetric condition, resulting in significant morbidity and even mortality of the mother and the child. Pritchard regimen is well established anticonvulsant protocol with good result in the management of eclampsia. To reduce the MgSO4 toxicity in low weight Indian women, a low dose regimen is tried. The low dose protocol is--a loading dose of 4 gm of MgSO4 slow IV; followed by a maintenance dose of 2 gms of MgSO4 slow IV every three hours; continued for 24 hours after delivery or 24 hours after last convulsion, whichever is later; If a convulsion occurs during treatment, an additional dose of 2 gms of MgSO4 is given slow IV in addition to the regular dose. During calendar years 2017, 2018,123 women were treated for eclampsia. 69 women got admitted for eclampsia, 15 had eclampsia after admission, 39 women were referred from other hospitals for management. 60% had antenatal or antepartum eclampsia. One third had postpartum eclampsia, the remaining being intrapartum cases. 40% of women had BP less than 160/110 and 60% above 160/110 mm of Hg. Of the 81 direct admissions--two thirds had eclampsia at or after 37 weeks; 60% had vaginal delivery unaided; 1/6 had instrumental vaginal delivery; and in 1/4th of women, the termination was done by LSCS. Of these 81 women, 13 were admitted with absent FH; 5 had intrapartum fetal death; of the 63 live births, 90% fair Apgar score; 10% with poor Apgar score at 5 minutes of delivery; there were 3 early neonatal deaths. One woman had eclampsia with 10 fits, went into coma and died. Others are well at discharge. Low dose MgSO4 regimen is equally efficacious as Pritchard`s regimen. Maternal and fetal morbidity and mortality were almost same in the low dose regimen when compared with Pritchard regimen.
Introduction
Eclampsia is defined as the occurrence of generalized convulsion(s) and/or coma associated with signs of pre-eclampsia during pregnancy, labor or within 7 days of delivery and not caused by epilepsy or other convulsive disorders. In the absence of a high blood pressure or if the convulsions occur after day 7 postpartum, the condition is referred to as atypical eclampsia. The incidence of eclampsia varies widely from 1 in 100 to 1 in 2000 pregnancies. It is estimated that 50,000 women die of eclampsia every year eclampsia is, most of which occur in developing countries.
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The Eclampsia Trial Collaborative Group Study concluded that magnesium sulphate was safer and better than phenytoin and diazepam. Additional advantages of magnesium sulphate therapy are lower cost, ease of administration and less sedation than diazepam and phenytoin. Magnesium sulphate also appears to selectively increase cerebral blood flow and oxygen consumption in women with eclampsia which is not true for other anticonvulsants. 4 The World Health Organisation has also recommended magnesium sulphate as the most effective, safe and low cost drug for the treatment of eclampsia. 31 There are principally two main regimens available for the administration of MgSO 4 . In the Pritchard Regimen, the loading bolus dose of 4 gram of MgSO 4 is given slowly intravenously over 5-10 minutes and this is followed immediately by 10 gram deep intramuscular injectionhalf in each buttock. Maintenance dose consist of 5 gram deep intramuscular injection into alternate buttock 4 hourly. 23 In Zuspan Regimen, the loading dose consists of an initial intravenous dose of 4 gram slowly over 5-10 minutes followed by a maintenance dose of 1-2 gram every hour given by an infusion pump. 32 The authors have suggested that the dose of magnesium sulphate should be limited in women who are known to have lower weight. Women in India especially from rural areas or from low socio-economic strata tend to have smaller weights. Administering Pritchard regime might prove hazardous in these low weight women and there is possibility of most dreadful respiratory failure. 23 With this in mind, various Indian authors have used low dose of magnesium sulphate and the outcomes were comparable with high dose regimens. 25, 15, 27 We, in our study, shall be using low dose magnesium sulphate for treatment of eclampsia. The toxicity of drug shall be monitored using clinical parameters which include knee-jerk (should be present), respiratory rate (should be more than 16 per minute) and urine output (should be more than 30 millilitre per hour). The first warning sign of toxicity is loss of knee-jerk. The clinical parameters of toxicity remaining within normal limits, serum magnesium level monitoring is not required. 29 Our present study using low dose magnesium sulphate therapy has been planned to evaluate the maternal and perinatal outcome in all patients of eclampsia admitted in our institution.
Aims
1. To evaluate maternal outcome with low dose magnesium sulphate therapy in patients admitted with and those who develop eclampsia after admission. 2. To evaluate perinatal outcome in all the patients given magnesium sulphate low dose therapy. 3. To evaluate fit recurrence rate and failure of treatment in these patients.
Material and Methods
The present study was conducted in the Postgraduate Department of Obstetrics and Gynaecology, Vinayaka Mission Medical College and Hospital, Karaikal, Pondicherry for a period of two calendar years of 2017 & 2018.
All the women who were admitted in Obstetrics Emergency Ward of Hospital with eclampsia and also women hospitalized for severe pre eclampsia, who had fits during antenatal, intrapartum or postpartum period. Anti convulsant protocol for eclampsia: Loading dose of4 g magnesium sulfate to be given intravenously, diluted in 20 cc of 5% dextrose, slower over 15-20 minutes. Maintenance dose of2 g magnesium sulfate intravenously, similarly diluted to be given 3 hourly till 24 hours after delivery or after last convulsion, whichever is later. For recurrent convulsions-If convulsion occurs half-an-hour after the loading dose, then only it is called recurrence of convulsions and in that case an additional dose of 2 g intravenously to be given and previous dose schedule of three hourly injections to be continued. Failure of treatment would mean uncontrolled convulsions even after 2 additional doses.
All the patients are monitored on clinical criteria. Before each dose of magnesium sulfate, toxicity in the form of deep tendon reflexes, urine output and respiratory rate was assessed. Intravenous Labetalol was used as first line antihypertensive therapy, unless contraindicated, in patients who had systolic blood pressure > 160 mmHg or diastolic blood pressure > 110 mmHg to prevent cerebrovascular accidents. Hydration is maintained by Ringer lactate solution 1000 cc over 24 hours and intravenous fluids to be restricted to prevent circulatory overload. Eclampsia patients were encouraged to take fluids orally as soon as they recover consciousness. Termination of pregnancy was undertaken in all cases of eclampsia. Delivery was expedited in the form of induction/augmentation of labour or LSCS depending upon assessment of each case.
Results
During the study period, 123 women were treated for eclampsia. The findings of the study were- Out of 123 patients 8.91 % patients had systolic blood pressure more than 200mmHg at the time of admission to our hospital. 62 (50.39%) patients had SBP more than or equal to 160 mmHg but less than 200mmHg. Diastolic BP ranged from 90-118mm of Hg.75 patients (60.97%) had diastolic pressure mpre than 110 mm of Hg. Seventy five percent of women were in labour and twenty five percent were not in labour. In majority of the cases duration of hospital stay was less than 6 days. About 40 percent of the patients had hospital stay of more than 6 days. 
Discussion
In the present study 123 patients of eclampsia were studied. The patients were given magnesium sulphate low dose regimen and were evaluated for the control of fits, recurrence of fits, complications maternal mortality/morbidity, and perinatal mortality and morbidity. Sixty percentage of women were less than 25 years of age, the median age being 24 years. The greater incidence in the younger age groups is reflective of the fact that the disease is more prevalent in primigravidae. Analysis of parity status reveals that 72.36 % of the patients in this study were primigravidae and Eclampsia is associated with high perinatal mortality. In this study of 81 women, 13 were admitted with absent FH. In the 68 women who delivered, there were 5 intrapartum deaths. 60 babies were born alive; Ten of these were born with low apgar. They were revived and three babies had early neonatal death. with low apgar. Perinatal mortality was 11.76%. Sadhna et al (1988) have noted a perinatal mortality rate of 9.57%with standard regimen of magnesium sulphate quite similar to that of 9.5% reported by Nagar et al (1988).
Conclusions
The low dose Magnesium sulphate regimen is equally efficacious as Pritchard regimen in control of convulsions in eclampsia. The low dose regimen compares well with Pritchard regimen in terms of maternal mortality, morbidity and perinatal mortality, morbidity.
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